CA
GPCR icon

Clearstead Advisors’s Structure Therapeutics GPCR Stock Holding History

Clearstead Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-67
Closed -$1.16K – 2794
2025
Q1 		$1.16K Hold
67
– – ﹤0.01% 1975
2024
Q4 		$1.82K Hold
67
– – ﹤0.01% 1856
2024
Q3 		$2.94K Hold
67
– – ﹤0.01% 1787
2024
Q2 		$2.63K Buy
67
+8
+14% +$328 ﹤0.01% 1786
2024
Q1 		$2.12K Hold
59
– – ﹤0.01% 1303
2023
Q4 		$2.4K Sell
59
-11
-16% -$630 ﹤0.01% 1260
2023
Q3 		$3.53K Buy
+70
New +$2.26K ﹤0.01% 1307

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Clearstead Advisors's GPCR Position: Q2 2025 in Review

Clearstead Advisors sold out of Structure Therapeutics (GPCR) in Q2 2025, closing a stake of 67 shares — an estimated $1.16K sold.

Clearstead Advisors first reported a position in GPCR in Q3 2023 and held it in 7 quarters. The position peaked at $3.53K in Q3 2023. 172 funds tracked by Wall St. Rank hold GPCR as of Q2 2025.

  • Clearstead Advisors reported no remaining Structure Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Clearstead Advisors sold 67 Structure Therapeutics shares in Q2 2025, an estimated $1.16K.
  • Clearstead Advisors first reported a position in Structure Therapeutics in Q3 2023 and held it in 7 quarters.
  • Clearstead Advisors's Structure Therapeutics position peaked at $3.53K in Q3 2023.
  • 172 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2025.

Based on Clearstead Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.